Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GPX4 | P36969 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510216 | 0.78 | POLB (0.40) | KMT2ATSHRPOLB | |
| SCHEMBL8959105 | 0.78 | POLB (0.40) | KMT2ATSHRPOLB | |
| SCHEMBL28380224 | 0.76 | ALDH1A1 (0.35) | ALDH1A1ATMGPX4KDM4ENPC1 | |
| SCHEMBL172075 | 0.73 | KDM4E (0.43) | ALDH1A1KMT2AATMKDM4EPOLB | |
| SCHEMBL6467731 | 0.72 | — | — | |
| SCHEMBL5237434 | 0.72 | ALDH1A1 (0.37) | ALDH1A1KMT2AATMTSHRGPX4 | |
| SCHEMBL5489568 | 0.72 | KDM4E (0.49) | ALDH1A1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL12123957 | 0.71 | ALDH1A1 (0.34) | ALDH1A1ATMGPX4KDM4ENPC1 | |
| SCHEMBL9610481 | 0.71 | ACP3 (0.42) | POLBHTT | |
| SCHEMBL17247980 | 0.70 | ALDH1A1 (0.31) | ALDH1A1KMT2AATMGPX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176866-A1 | Complexes having adjuvant activity | POLYTHERICS LIMITED (GB) | 2009-07-09 | — | — | US | disclosed |
| US-20090176866-A1 | Complexes having adjuvant activity | POLYTHERICS LIMITED (GB) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176866-A1 | Complexes having adjuvant activity | MYD88, TLR3, TLR9 | ALDH1A1 2687/4885KMT2A 2389/4885ATM 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.